tradingkey.logo
tradingkey.logo
Pesquisar

Evolus Inc

EOLS
Adicionar à lista de desejos
6.500USD
-0.080-1.22%
Fechamento 05/15, 16:00ETCotações atrasadas em 15 min
428.06MValor de mercado
PerdaP/L TTM

Mais detalhes de Evolus Inc Empresa

Evolus, Inc. is a performance beauty company. Its primary market is the cash-pay aesthetic market, which consists of medical products. Its product candidates represent two of the product categories within medical aesthetics, injectable neurotoxins and injectable hyaluronic acid gels. Its product candidates include Jeuveau and Evolysse. Jeuveau is its commercially available proprietary 900 kilodalton (kDa), purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Jeuveau offers a 900kDa botulinum toxin alternative to BOTOX (onabotulinumtoxinA). Jeuveau is available in the United States, Canada, and certain European markets. Evolysse is a line of hyaluronic acid dermal fillers which utilizes first-generation cold technology. The line includes a variety of products, including mid face, nasolabial folds, lips and eyes in the United States and Europe.

Informações de Evolus Inc

Código da empresaEOLS
Nome da EmpresaEvolus Inc
Data de listagemFeb 08, 2018
CEOMoatazedi (David)
Número de funcionários332
Tipo de títulosOrdinary Share
Fim do ano fiscalFeb 08
Endereço520 Newport Center Dr Ste 1200
CidadeNEWPORT BEACH
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal92660-7022
Telefone19492844555
Sitehttps://www.evolus.com/
Código da empresaEOLS
Data de listagemFeb 08, 2018
CEOMoatazedi (David)

Executivos da empresa Evolus Inc

Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Vikram Malik
Mr. Vikram Malik
Independent Chairman of the Board
Independent Chairman of the Board
243.01K
-28.17%
Ms. Tatjana Mitchell
Ms. Tatjana Mitchell
Chief Financial Officer
Chief Financial Officer
226.09K
+53.73%
Mr. David Moatazedi
Mr. David Moatazedi
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
105.11K
-128.12%
Mrs. Brady Stewart
Mrs. Brady Stewart
Independent Director
Independent Director
88.63K
-43.10%
Mr. David N. Gill
Mr. David N. Gill
Independent Director
Independent Director
41.33K
-92.42%
Dr. Rui L. Avelar, M.D.
Dr. Rui L. Avelar, M.D.
Chief Medical Officer, Head - Research and Development
Chief Medical Officer, Head - Research and Development
--
--
Ms. Karah Parschauer, J.D.
Ms. Karah Parschauer, J.D.
Independent Director
Independent Director
--
--
Mr. Nareg Sagherian
Mr. Nareg Sagherian
Investor Relations
Investor Relations
--
--
Mr. Albert G. White, III
Mr. Albert G. White, III
Independent Director
Independent Director
--
--
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Vikram Malik
Mr. Vikram Malik
Independent Chairman of the Board
Independent Chairman of the Board
243.01K
-28.17%
Ms. Tatjana Mitchell
Ms. Tatjana Mitchell
Chief Financial Officer
Chief Financial Officer
226.09K
+53.73%
Mr. David Moatazedi
Mr. David Moatazedi
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
105.11K
-128.12%
Mrs. Brady Stewart
Mrs. Brady Stewart
Independent Director
Independent Director
88.63K
-43.10%
Mr. David N. Gill
Mr. David N. Gill
Independent Director
Independent Director
41.33K
-92.42%
Dr. Rui L. Avelar, M.D.
Dr. Rui L. Avelar, M.D.
Chief Medical Officer, Head - Research and Development
Chief Medical Officer, Head - Research and Development
--
--

Detalhamento da receita

Os dados relevantes ainda não foram divulgados pela empresa.
Os dados relevantes ainda não foram divulgados pela empresa.
Por Empresa
Por Região
Os dados relevantes ainda não foram divulgados pela empresa.

Distribuição de ações

Atualizado em: dom, 10 de mai
Atualizado em: dom, 10 de mai
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
Lynch (Timothy Patrick)
9.76%
Nantahala Capital Management, LLC
8.84%
BlackRock Institutional Trust Company, N.A.
5.62%
Braidwell LP
4.72%
Frazier Life Sciences Management, L.P.
3.99%
Outro
67.07%
Investidores
Investidores
Proporção
Lynch (Timothy Patrick)
9.76%
Nantahala Capital Management, LLC
8.84%
BlackRock Institutional Trust Company, N.A.
5.62%
Braidwell LP
4.72%
Frazier Life Sciences Management, L.P.
3.99%
Outro
67.07%
Tipos de investidores
Investidores
Proporção
Hedge Fund
32.26%
Investment Advisor
19.57%
Investment Advisor/Hedge Fund
15.65%
Individual Investor
11.44%
Private Equity
3.99%
Research Firm
3.79%
Corporation
3.24%
Insurance Company
0.20%
Pension Fund
0.15%
Outro
9.70%

Participação acionária institucional

Atualizado em: qua, 1 de abr
Atualizado em: qua, 1 de abr
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2026Q1
391
50.03M
75.98%
-16.02M
2025Q4
356
58.38M
89.22%
--
2025Q3
366
58.59M
90.20%
-409.50K
2025Q2
368
58.97M
91.09%
+3.93M
2025Q1
354
55.05M
88.70%
-1.35M
2024Q4
343
52.59M
87.55%
+1.63M
2024Q3
334
50.95M
89.20%
-1.08M
2024Q2
328
52.17M
86.99%
+2.08M
2024Q1
314
50.10M
82.52%
-553.42K
2023Q4
296
45.99M
83.45%
+2.48M
Ver Mais

Atividade dos acionistas

Nome
Ações detidas
Proporção
Variação
Var. %
Data
Lynch (Timothy Patrick)
6.43M
9.88%
+1.29M
+25.17%
Dec 31, 2025
Nantahala Capital Management, LLC
5.82M
8.95%
+93.79K
+1.64%
Dec 31, 2025
BlackRock Institutional Trust Company, N.A.
3.70M
5.69%
-285.94K
-7.17%
Dec 31, 2025
Braidwell LP
3.11M
4.77%
+3.11M
--
Dec 31, 2025
Frazier Life Sciences Management, L.P.
2.63M
4.04%
--
--
Dec 31, 2025
Medy Tox Inc
2.14M
3.28%
-1.24M
-36.82%
Dec 31, 2024
Millennium Management LLC
2.09M
3.22%
+234.03K
+12.59%
Dec 31, 2025
Stonepine Capital Management, LLC
1.63M
2.51%
+95.20K
+6.20%
Dec 31, 2025
State Street Investment Management (US)
1.57M
2.42%
+59.63K
+3.94%
Dec 31, 2025
Ver Mais

ETFs Relacionados

Atualizado em: sáb, 6 de dez
Atualizado em: sáb, 6 de dez
Nome
Proporção
State Street SPDR S&P Pharmaceuticals ETF
0.97%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
0.93%
iShares U.S. Pharmaceuticals ETF
0.15%
iShares Micro-Cap ETF
0.07%
ProShares Ultra Nasdaq Biotechnology
0.06%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
0.06%
Invesco Nasdaq Biotechnology ETF
0.04%
ProShares Hedge Replication ETF
0.02%
iShares Russell 2000 Growth ETF
0.02%
Schwab U.S. Small-Cap ETF
0.01%
Ver Mais
State Street SPDR S&P Pharmaceuticals ETF
Proporção0.97%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
Proporção0.93%
iShares U.S. Pharmaceuticals ETF
Proporção0.15%
iShares Micro-Cap ETF
Proporção0.07%
ProShares Ultra Nasdaq Biotechnology
Proporção0.06%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
Proporção0.06%
Invesco Nasdaq Biotechnology ETF
Proporção0.04%
ProShares Hedge Replication ETF
Proporção0.02%
iShares Russell 2000 Growth ETF
Proporção0.02%
Schwab U.S. Small-Cap ETF
Proporção0.01%

Dividendo

Um total de 0.00 USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados

Desdobramento de ações

Data
Data ex-dividendo
Tipo
Proporção
Sem dados
Data
Data ex-dividendo
Tipo
Proporção
Sem dados
KeyAI